安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- What Is T-Dxd For Breast Cancer? | Effective Treatment
T-Dxd represents a significant leap forward in treating HER2-positive breast cancer by harnessing targeted therapy’s power combined with potent chemotherapy action against resistant tumors
- FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer . . .
On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist
- FDA Approves T-DXd in HR+, HER2-Low Ultralow Breast Cancer
The FDA has granted approval to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for treating adult patients with unresectable or metastatic, hormone receptor–positive, HER2-low (immunohistochemistry [IHC] 1+ or 2+ ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed
- T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or . . .
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has been approved by the U S Food and Drug Administration (FDA) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+ in situ hybridization–negative) or HER2-ultralow (IHC 0 with
- Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer
Trastuzumab deruxtecan, also known as T-DXd, “is the first HER2-targeted therapy shown to provide clinically meaningful improvement in progression-free and overall survival compared with standard chemotherapy in people with HER2-low metastatic breast cancer,” Dr Modi said at the meeting
- T DXd for HER2-Positive Cancer: Mechanism and Pharmacokinetics
T-DXd binds to human epidermal growth factor receptor 2 (HER2), a protein overexpressed in certain cancers, ensuring that its cytotoxic payload is delivered primarily to malignant cells This targeted approach minimizes systemic toxicity while maximizing therapeutic efficacy
- Expert Insights into the T-DXd Approval for HER2-Low or Ultralow Breast . . .
In January 2025, the FDA approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for patients with unresectable or metastatic hormone receptor (HR)–positive, HER2-low or HER2-ultralow breast cancer, based on findings from the phase 3 DESTINY-Breast06 trial (NCT04494425) 1,2
- HER2-targeting Therapy for HER2-ultralow Breast Cancer
T-DXd is a targeted therapy called an antibody-drug conjugate The antibody part, trastuzumab, binds to the protein HER2, which is overexpressed on the surface of some types of breast cancer cells
|
|
|